Sengenics is a functional proteomics company that leverages its patented KREX protein folding technology to discover autoantibody biomarker signature for drug response prediction, patient stratification and development of companion diagnostics. Our technology ensure that all microarray proteins are full length, correctly folded and functional, enabling specific and quantitative antibody binding to conformational epitopes.
The company has a global footprint with multiple corporate and research sites across the world with customers and collaborators that include top pharma, biotech and ivy league academic institutions in North America, Europe, and Asia.
The company has a global footprint with multiple corporate and research sites across the world with customers and collaborators that include top pharma, biotech and ivy league academic institutions in North America, Europe, and Asia.
Location: United States, Massachusetts, Billerica
Employees: 51-200
Phone: +44 1223 926588
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Summa Equi... | summaequit... |
Mentions in press and media 4
| Date | Title | Description |
| 30.07.2024 | Sengenics Corporation Unveils i-Ome® Cancer: A Breakthrough in Cancer Precision Medicine | Revolutionizing Biomarker Discovery with a High-Throughput Immunoproteomic Platform BOSTON, July 30, 2024 /PRNewswire/ -- Sengenics Corporation LLC is proud to announce the launch of i-Ome Cancer, a cutting-edge research tool designed to tr... |
| 12.03.2024 | Proteomics Market is growing at a CAGR of 15.15% from 2024 to 2030 by Exactitude Consultancy | proteomics market The Exactitude Consultancy Proteomics Market Report – Size, Trends, and Forecast 2024-2030 The proteomics market is experiencing high demand due to advancements in research, personalized medicine, and drug development.” — ... |
| 27.02.2024 | Sengenics Corporation Announces Key Distributor in China | Sengenics Partners with Shanghai Universal Biotech Co., Ltd. (UniV) to Expand Reach of Immunoprofiling Products and Services in China BOSTON, Feb. 27, 2024 /PRNewswire/ -- Sengenics Corporation LLC, a pioneer in the field of immunoproteomic... |
| - | Sengenics Launches AxCESS, a Research Services Suite to Enable Wider Accessibility to Protein Arrays Developed Using its Patented KREX Protein Folding Technology | LONDON--(BUSINESS WIRE)--Mar 2, 2021-- Sengenics, the Functional Proteomics Company, today announced the commercial launch of the Sengenics AxCESS research services suite which features three new KREX-based functional protein arrays develop... |